Status:
COMPLETED
Bioequivalence of Two Tablet Forms of MK0974 (0974-045)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Migraine
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
This study will evaluate the bioequivalence of two solid dose formulations of MK0974.
Eligibility Criteria
Inclusion
- Subject is in good health
- Subject is a non-smoker
- Subject is willing to comply with the study restrictions
Exclusion
- Subject has a history of stroke, chronic seizures, or major neurological disorder
- Subject has a history of cancer
- Subject is a nursing mother
- Subject has or has a history of any disease or condition that might make participation in the study unsafe or that might confound the results of the study
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00965887
Start Date
March 1 2008
End Date
May 1 2008
Last Update
July 7 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.